MRNA technology takes on Hard-to-Treat multiple myeloma
NCT ID NCT07362732
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new mRNA-based drug called WGb-0302 in 20 adults with recurrent or treatment-resistant multiple myeloma and other blood cancers. The therapy uses lipid nanoparticles to deliver mRNA that targets BCMA, a protein on cancer cells. The main goals are to check safety and find the right dose, not yet to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- WGb-0302 injection (mRNA therapy targeting BCMA, delivered via lipid nanoparticles)
- What this could lead to
- If it works, this could point toward a new treatment option for patients with hard-to-treat multiple myeloma who have run out of standard therapies.
- What could go wrong
- This is a very early, small safety study (20 people) with no guarantee of effectiveness. The treatment may cause side effects or fail to control the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a simple blood test outsmart deadly fungal infections in blood cancer?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?